KLK3 and prostate carcinoma: Chiu and Lin’s study (Chiu and Lin, 2008) also revealed that luteolin can inhibit the proliferation of prostate cancer cells and induce apoptosis of prostate cancer LNCaP cells, while reducing prostate-specific antigen (PSA) level and Androgen receptor (AR) expression, leading to AR degradation by reducing the association between AR and heat shock protein 90, indicating that luteolin plays an anti-cancer role by targeting AR and may be used for the chemoprevention and treatment of prostate cancer.